Αποτελέσματα Αναζήτησης
CAV-2 is endemic in healthy dog populations worldwide and is a significant viral cause of CIRD, particularly when combined with viral or bacterial co-infections. Vaccination with an MLV vaccine is critical for reduction of clinical signs and to prevent canine infectious hepatitis.
17 Αυγ 2022 · Canine adenovirus type 2 (CAV-2) is considered a core vaccine, primarily because it is necessary for the prevention of canine adenovirus type 1 (CAV-1) (against which it cross-protects), 18 the cause of infectious canine hepatitis, historically recognized as a severe and often fatal disease of canids.
14 Ιουλ 2011 · A vaccine is available to prevent CAV-2 infection. However, it is important to realize that the vaccine does not completely prevent dogs from contracting CAV-2. Rather, the vaccine limits the severity of infection so that vaccinated dogs typically experience a milder form of the disease.
Canine adenovirus type 2 (CAV-2) is related to the hepatitis virus, canine adenovirus type 1 (CAV-1). CAV-2 is used in vaccines to provide protection against canine infectious hepatitis. CAV-2 is also one of the causes of infectious tracheobronchitis, also known as canine cough. 30.
21 Οκτ 2020 · Methods: Ninety-seven healthy adult dogs (last vaccination ≥12 months) were re-vaccinated with a modified live CAV-2 vaccine. Anti-CAV antibodies were measured before vaccination (day 0), and after re-vaccination (day 7, 28) by virus neutralization.
1 Σεπ 2020 · We constructed a new canine adenovirus type 2 (CAV-2) vaccine candidate using the recently isolated Korean CAV-2 strain; we termed the vaccine APQA1701-40P and evaluated its safety and immunogenicity in dogs.
Clinical Features and Epidemiology. Disease induced by canine adenovirus 1 is well controlled by vaccination in many countries and, therefore, most infections are subclinical or manifest as undifferentiated respiratory disease.
